News
OCGN
1.000
-3.85%
-0.040
Press Release: Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Dow Jones · 1d ago
Ocugen Adjourns Special Meeting on Authorized Share Increase
TipRanks · 1d ago
Transcript: Ocugen Q2 2026 Earnings Conference Call
Benzinga · 1d ago
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Barchart · 1d ago
Weekly Report: what happened at OCGN last week (0928-1002)?
Weekly Report · 2d ago
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026
Seeking Alpha · 5d ago
Ocugen Inc. Stock Sheds 5.5%, Underperforms Market
Dow Jones · 09/30 20:33
Analyst Maintains Buy Rating on Ocugen as OCU400’s Early Revenue Pathway and Phase 3 Upside Support Unchanged $11 Price Target
TipRanks · 09/30 13:16
Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX), Vir Biotechnology (VIR) and Ocugen (OCGN)
TipRanks · 09/30 08:00
Ocugen Inc. Stock Rallies 5.8%, Outperforms Market
Dow Jones · 09/29 20:33
Ocugen to Participate in Upcoming October Investor and Industry Conferences
Barchart · 09/29 06:02
Analysts Conflicted on These Healthcare Names: Ocugen (OCGN), Aveanna Healthcare Holdings (AVAH) and Universal Health (UHS)
TipRanks · 09/28 13:10
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN)
TipRanks · 09/28 11:00
Weekly Report: what happened at OCGN last week (0921-0925)?
Weekly Report · 09/28 09:33
Ocugen Gains Bahamas Approval Pathway For OCU400 Retinitis Pigmentosa Therapy
NASDAQ · 09/25 14:45
Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas
Dow Jones · 09/25 11:49
Ocugen Receives Bahamas Regulator Provisional Approval For OCU400 Has Been Granted Approval And Priority Designation; The Company Will Supply OCU400 Through An EAP, With Goal Of Treating First RP Patient Within 90 Days
Benzinga · 09/25 11:13
Ocugen’s OCU400 granted provisional approval, priority designation from LARTA
TipRanks · 09/25 11:10
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
Barchart · 09/25 06:02
Ocugen Inc. Stock Slips 3.8%, Underperforms Market
Dow Jones · 09/23 20:34
More
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.